UB Paderborn / Katalog / Suche / in CDI

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Journal of hepatology, 2012-04, Vol.56, p.S436-S436

2012

Link zum Volltext

Verfügbarkeit prüfen

431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS® ) PLUS RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S175-S175

2011

Link zum Volltext

Verfügbarkeit prüfen

292 IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400,000 IU/ML WEIGHING ≥85 kg

Journal of hepatology, 2010, Vol.52, p.S122-S122

2010

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of hepatitis C virus infection in patients with COPD

Epidemiology and infection, 2010-02, Vol.138 (2), p.167-173

2010

Link zum Volltext

Verfügbarkeit prüfen

P2-76 Antibiotics for hepatic encephalopathy: systematic review of randomised controlled trials

Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A240-A241

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort

Journal of viral hepatitis, 2014-05, Vol.21 (5), p.377-380

2014

Link zum Volltext

Verfügbarkeit prüfen

792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY

Journal of hepatology, 2013-04, Vol.58, p.S323-S323

2013

Link zum Volltext

Verfügbarkeit prüfen

1098 HCV RNA <15IU/ML AT WEEK 4 IS HIGHLY PREDICTIVE OF SVR AMONG HCV G2/3 PATIENTS RECEIVING PEGINTERFERON ALFA-2A/RBV: FINAL RESULTS FROM POTENTE STUDY

Journal of hepatology, 2012-04, Vol.56, p.S432-S432

2012

Link zum Volltext

Verfügbarkeit prüfen

73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY

Journal of hepatology, 2012-04, Vol.56, p.S32-S32

2012

Link zum Volltext

Verfügbarkeit prüfen

539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S214-S214

2012

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C

The American journal of gastroenterology, 2004-08, Vol.99 (8), p.1490-1496

2004

Link zum Volltext

Verfügbarkeit prüfen

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2009-11, Vol.16 (11), p.784-789

2009

Link zum Volltext

Verfügbarkeit prüfen

432 FIBROSIS STAGING PREDICTS VIROLOGICAL RESPONSE IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL

Journal of hepatology, 2011-03, Vol.54, p.S175-S176

2011

Link zum Volltext

Verfügbarkeit prüfen

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2006-03, Vol.354 (10), p.1011-1020

2006

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C

The American journal of gastroenterology, 2004-08, Vol.99 (8), p.1490-1496

2004

Link zum Volltext

Verfügbarkeit prüfen

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

Journal of hepatology, 2010, Vol.52, p.S390-S391

2010

Link zum Volltext

Verfügbarkeit prüfen

293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS

Journal of hepatology, 2010, Vol.52, p.S123-S123

2010

Link zum Volltext

Verfügbarkeit prüfen

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Journal of hepatology, 2024-02, Vol.80 (2), p.232-242

2024

Link zum Volltext

Verfügbarkeit prüfen

999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS

Journal of hepatology, 2008, Vol.48, p.S374-S374

2008

Link zum Volltext

Verfügbarkeit prüfen

Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy

The Brazilian journal of infectious diseases, 2006-02, Vol.10 (1), p.11-16

2006

Link zum Volltext

Verfügbarkeit prüfen

[628] USE OF LOW-DOSE PEGINTERFERON a-2a (40 kD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY

Journal of hepatology, 2007, Vol.46, p.S237-S238

2007

Link zum Volltext

Verfügbarkeit prüfen

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION PATIENTS

Value in health, 2010, Vol.13 (7), p.A368-A368

2010

Link zum Volltext

Verfügbarkeit prüfen

[517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS

Journal of hepatology, 2007, Vol.46, p.S197-S197

2007

Link zum Volltext

Verfügbarkeit prüfen

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

Hepatology (Baltimore, Md.), 2008-07, Vol.48 (1), p.99-108

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS® ) PLUS RIBAVIRIN

292 IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400,000 IU/ML WEIGHING ≥85 kg

New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society

Prevalence of hepatitis C virus infection in patients with COPD

P2-76 Antibiotics for hepatic encephalopathy: systematic review of randomised controlled trials

Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort

792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY

1098 HCV RNA <15IU/ML AT WEEK 4 IS HIGHLY PREDICTIVE OF SVR AMONG HCV G2/3 PATIENTS RECEIVING PEGINTERFERON ALFA-2A/RBV: FINAL RESULTS FROM POTENTE STUDY

73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY

539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

432 FIBROSIS STAGING PREDICTS VIROLOGICAL RESPONSE IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

293 PREDICTORS OF RELAPSE AMONG PATIENTS TREATED WITH STANDARD OR INDUCTION DOSE PEGINTERFERON ALFA-2A (40KD) COMBINED WITH STANDARD OR HIGHER DOSE RIBAVIRIN IN DIFFICULT-TO-CURE PATIENTS

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

999 LOW-DOSE PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED, END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: FINAL STUDY RESULTS

Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy

[628] USE OF LOW-DOSE PEGINTERFERON a-2a (40 kD) (PEGASYS®) TO TREAT HEPATITIS C-INFECTED END-STAGE RENAL DISEASE PATIENTS UNDERGOING HAEMODIALYSIS: INTERIM RESULTS FROM A RANDOMISED STUDY

PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION PATIENTS

[517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

Suchergebnisse filtern